雷帕鸣效果好吗？

In 1999, it was officially approved by the US FDA for the treatment of kidney transplant patients aged 13 or above to prevent organ rejection. In 2002, Rapamin was approved for marketing in my country, bringing new options for the treatment of domestic patients. The original manufacturer of Rapamide is Pfizer. However, when the original drug is relatively expensive, many patients have begun to choose to buy Rapamide produced by Biocon in India.

The price of Rapamide produced by Biocon in India is relatively low, so many patients are also concerned about its effect. Is the Rapamide produced by Biocon in India effective?

Let’s first learn about the Indian Biocon company. Biocon is one of India's three largest biotechnology companies, and its goal is to achieve health equity. The four global businesses include generic drugs, biosimilars, research services and novel biologics. The generic drug of Rapamide produced by Biocon in India is the same as the original drug in terms of drug ingredients, usage and dosage, and the therapeutic effect is also almost the same.

Rapamin combined with low-dose cyclosporine A is a better immunosuppressive treatment option after renal transplantation, and the use of rapamin can reduce the dose of CNI. After renal transplantation, it is safe and effective to control the steady-state trough concentration of rapamycin at 4-8ng/ml or 5-8ng/ml. Rapamin also reduces the incidence of non-melanoma skin cancer after kidney transplantation. In addition, rapamycin has also achieved good anti-rejection effects after heart transplantation, lung transplantation, corneal transplantation and other transplants, but the therapeutic concentration has not been reported.

The use of can not only effectively reduce the risk of rejection, but is also relatively safe. Patients should start taking it as soon as possible after transplantation. If you need to purchase the Indian version of Rapamin, you can further consult the medical companion travel service for detailed information.

Recommended related hot articles: /newsDetail/89013.html